Shots:

• The companies collaborate to conduct P-I/II clinical trial assessing CyPep-1 in patients to treat advanced solid cancers. SMS-Oncology will focus on developing protocol and giving guidance on patient inclusion criteria plus investigational sites for further movement to clinic
• The P-I/II multicenter trial will be conducted in Europe evaluating safety- efficacy & PK or intratumoral of CyPep-1 in patients with advanced solid cancers enrolling 18 patients- with its expected initiation in Q4’19. Additionally- Cytovation is currently starting first-in-human trial with intratumoral injection of CyPep-1- aiming to reach first in patient (FPI) in H2’19  
• Cytovation’s CyPep-1 is lead investigational first-in-class lytic agent targeted for solid tumors in both injectable and cream formulations- currently being evaluated in P-I trial in patients with HPV-induced cutaneous tumors (warts)

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Twitter